99 related articles for article (PubMed ID: 21955928)
1. PET response and tumor stabilization under erlotinib and bevacizumab treatment of an intracranial lesion non-invasively diagnosed as likely chordoma.
Asklund T; Danfors T; Henriksson R
Clin Neuropathol; 2011; 30(5):242-6. PubMed ID: 21955928
[TBL] [Abstract][Full Text] [Related]
2. Durable complete response to chemotherapy in an infant with a clival chordoma.
Al-Rahawan MM; Siebert JD; Mitchell CS; Smith SD
Pediatr Blood Cancer; 2012 Aug; 59(2):323-5. PubMed ID: 21922644
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
4. Durable stabilization of three chordoma cases by bevacizumab and erlotinib.
Asklund T; Sandström M; Shahidi S; Riklund K; Henriksson R
Acta Oncol; 2014 Jul; 53(7):980-4. PubMed ID: 24456503
[No Abstract] [Full Text] [Related]
5. Salvage with erlotinib plus bevacizumab: not in NSCLC.
Sculier JP; Meert AP; Berghmans T
Lancet; 2011 May; 377(9780):1810-2. PubMed ID: 21621709
[No Abstract] [Full Text] [Related]
6. Management and outcome of chordomas in the pediatric population: The Hospital for Sick Children experience and review of the literature.
Tsitouras V; Wang S; Dirks P; Drake J; Bouffet E; Hawkins C; Laughlin S; Rutka JT
J Clin Neurosci; 2016 Dec; 34():169-176. PubMed ID: 27590862
[TBL] [Abstract][Full Text] [Related]
7. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
Socinski MA; Stinchcombe TE; Moore DT; Gettinger SN; Decker RH; Petty WJ; Blackstock AW; Schwartz G; Lankford S; Khandani A; Morris DE
J Clin Oncol; 2012 Nov; 30(32):3953-9. PubMed ID: 23045594
[TBL] [Abstract][Full Text] [Related]
8. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Lebellec L; Chauffert B; Blay JY; Le Cesne A; Chevreau C; Bompas E; Bertucci F; Cupissol D; Fabbro M; Saada-Bouzid E; Duffaud F; Feuvret L; Bonneville-Levard A; Bay JO; Vauleon E; Vinceneux A; Noel G; Penel N; Mir O
Eur J Cancer; 2017 Jul; 79():119-128. PubMed ID: 28478340
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous regression of a clival chordoma. Case report.
Bander ED; Kocharian G; Liechty B; Tsiouris AJ; Schwartz TH
Acta Neurochir (Wien); 2020 Feb; 162(2):433-436. PubMed ID: 31713157
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
Mammar H; Kerrou K; Nataf V; Pontvert D; Clemenceau S; Lot G; George B; Polivka M; Mokhtari K; Ferrand R; Feuvret L; Habrand JL; Pouysségur J; Mazure N; Talbot JN
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):681-7. PubMed ID: 22391104
[TBL] [Abstract][Full Text] [Related]
12. Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer.
Wakelee HA
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):17-21. PubMed ID: 24852399
[No Abstract] [Full Text] [Related]
13. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma.
Hof H; Welzel T; Debus J
Onkologie; 2006 Dec; 29(12):572-4. PubMed ID: 17202828
[TBL] [Abstract][Full Text] [Related]
14. Clival chordoma with drop metastases.
Nor FEM; Desai V; Chew LL
J Radiol Case Rep; 2018 Mar; 12(3):1-9. PubMed ID: 29875988
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
[TBL] [Abstract][Full Text] [Related]
16. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
[TBL] [Abstract][Full Text] [Related]
17. Response to imatinib plus sirolimus in advanced chordoma.
Stacchiotti S; Marrari A; Tamborini E; Palassini E; Virdis E; Messina A; Crippa F; Morosi C; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2009 Nov; 20(11):1886-94. PubMed ID: 19570961
[TBL] [Abstract][Full Text] [Related]
18. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium.
Hainsworth JD; Spigel DR; Greco FA; Shipley DL; Peyton J; Rubin M; Stipanov M; Meluch A
Cancer J; 2011; 17(5):267-72. PubMed ID: 21952273
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal Fluid Leak Rhinorrhea after Systemic Erlotinib Chemotherapy for Metastatic Lung Cancer: A Familiar Problem from an Unfamiliar Culprit.
Priddy B; Hardesty DA; Beer-Furlan A; Otto B; Prevedello DM
World Neurosurg; 2017 Dec; 108():992.e11-992.e14. PubMed ID: 28887281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
